The following industry sponsored contracts also have been received. View information on clinical trials enrolling patients at UNMC.
Samuel Cohen, M.D., Ph.D., pathology and microbiology – to evaluate the carcinogenicity of a compound with potential use in neurodegenerative diseases.
Howard Gendelman, M.D., pharmacology and experimental neuroscience – to evaluate the formation of Lewy bodies in Parkinson’s disease.
Thomas Porter, M.D., internal medicine/cardiology – for an interventional clinical trial to evaluate the efficacy of a contrast media commonly used to detect coronary artery disease in echocardiograms when used in concert with a stress agent currently used in an alternate imaging system. This trial is currently recruiting patients. View details regarding the study.
James Harper, M.D., pediatrics hematology & oncology – for clinical trials evaluating the safety, efficacy and pharmacokinetics of two compounds used in the treatment of bleeding disorders. Both trials are currently recruiting patients. Details can be found here and here.
and
Kari Simonsen, M.D., pediatrics infectious diseases – for a clinical trial to compare the safety and immunogenicity of a 5th dose combo booster regimen on pertussis, diphtheria and tetanus in children. This trial is currently recruiting patients. View details regarding the study.
John Colombo, M.D., pediatrics pulmonology – for a clinical trial to evaluate the efficacy and safety of a cystic fibrosis transmembrane regulator (CFTR) found to be effective in CF patients with one type of gene mutation in patients with a different gene mutation. This trial is currently recruiting patients. View details regarding the study.
Susan Swindells, M.B.B.S., internal medicine-infectious disease – for a clinical trial to evaluate a dosing strategy for a compound used in antiretroviral therapy in HIV-1 infected individuals. This trial is currently recruiting patients. View details regarding the study.
Edward Faber, D.O., internal medicine-oncology & hematology – for a clinical trial to determine whether the addition of a humanized monoclonal antibody to a chemotherapeutic regimen will increase progression free survival of patients with multiple myeloma. This trial is currently recruiting patients. View details regarding the study.